Male patients with newly diagnosed multiple myeloma (NDMM) tend to present with clinical features that correlate with a heavier disease burden compared with female populations, according to data from the IMAGE study published in Cancer.1
Based on multivariate analysis, patients who were male were more likely to have International Staging System (ISS) stage III disease at diagnosis (OR, 2.05; 95% CI, 1.22–3.46; P = .007), a high serum monoclonal protein (OR, 1.72; 95% CI, 1.15–2.56; P = .008), k light chain disease (OR, 1.60; 95% CI, 1.11–2.30; P = .01), and more end-organ damage (OR, 1.24; 95% CI, 1.02–1.50; P = .03) compared with patients who were female. When adjusting for various covariates including race, age, body mass index, and education, male populations with NDMM had a lower likelihood of presenting with light…